Disease Management Programs – A Time to Revisit

December 2, 2011

The Pharma industry landscape has changed dramatically over the last 5+ years. Consider the patent cliff underway; a weak R&D pipeline for blockbuster drugs; spiraling costs on multiple fronts including R&D and managed market rebates; increasing regulatory scrutiny across sales and marketing, and last but not least healthcare reform.